DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

Jonathan D. Licht

Research output: Contribution to journalShort surveypeer-review

46 Scopus citations

Abstract

DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.

Original languageEnglish
Pages (from-to)938-939
Number of pages2
JournalCell
Volume162
Issue number5
DOIs
StatePublished - 27 Aug 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension'. Together they form a unique fingerprint.

Cite this